These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30028616)

  • 1. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
    Lee HY; Fan SJ; Huang FI; Chao HY; Hsu KC; Lin TE; Yeh TK; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
    J Med Chem; 2018 Aug; 61(16):7087-7102. PubMed ID: 30028616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
    Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
    Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
    Fan SJ; Huang FI; Liou JP; Yang CR
    Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
    Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
    ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors.
    Hsu KC; Chu JC; Tseng HJ; Liu CI; Wang HC; Lin TE; Lee HS; Hsin LW; Wang AH; Lin CH; Huang WJ
    Eur J Med Chem; 2021 Jul; 219():113419. PubMed ID: 33845233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological activity of oxyevodiamine-based histone deacetylase 6 inhibitors.
    Li SY; Guo JS; Yang YJ
    J Asian Nat Prod Res; 2024 Nov; 26(11):1328-1338. PubMed ID: 38945152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
    Santini A; Tassinari E; Poeta E; Loi M; Ciani E; Trazzi S; Piccarducci R; Daniele S; Martini C; Pagliarani B; Tarozzi A; Bersani M; Spyrakis F; Danková D; Olsen CA; Soldati R; Tumiatti V; Montanari S; De Simone A; Milelli A
    ACS Chem Neurosci; 2024 Jun; 15(11):2099-2111. PubMed ID: 38747979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
    He F; Chou CJ; Scheiner M; Poeta E; Yuan Chen N; Gunesch S; Hoffmann M; Sotriffer C; Monti B; Maurice T; Decker M
    J Med Chem; 2021 Apr; 64(7):3794-3812. PubMed ID: 33769811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease.
    Liang T; Liu S; Dang B; Luan X; Guo Y; Steimbach RR; Hu J; Lu L; Yue P; Wang R; Zheng M; Gao J; Yin X; Chen X
    Eur J Med Chem; 2024 Sep; 275():116624. PubMed ID: 38925015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
    Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
    J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups.
    Han B; Gu X; Wang M; Wang H; Sun N; Yang X; Zhang Q
    Chem Biol Drug Des; 2024 May; 103(5):e14556. PubMed ID: 38772881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.
    Zhang C; Chou CJ
    Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.